CD274 and non-small cell lung carcinoma: Immunotherapies targeting programmed death-1 (PD-1) and programmed death-ligand 1 (PD-L1) have transformed NSCLC treatment by restoring antitumor immune activity, resulting in durable clinical responses in a subset of patients2.